Pfizer's shares have seen a significant decline of -30% since their peak in July 2024 and a -16.44% decrease in the past month, surpassing the market's -9.44% loss. While the company reported strong Q4 earnings, including a 37.20% EPS beat and a revenue increase of 2.89%, investor confidence remains low as the stock continues to struggle into 2025. With an expectation to earn between $61 billion and $64 billion for FY 2025, particularly with growth in oncology, the article explores future prospects for Pfizer amidst its historical decline.
Pfizer has seen a -30% decline in stock price since July, despite strong Q4 earnings and a dividend yield of 7.83%.
Despite excellent Q4 earnings, shares of Pfizer have struggled post-2025, demonstrating a significant decline from their all-time high in December 2021.
Pfizer forecasts FY 2025 revenues of $61 billion to $64 billion, buoyed by oncology sales from drugs in development, despite weaker COVID sales.
The company's enduring legacy includes significant contributions to pharmaceuticals, yet it has disappointed shareholders over the last five years, losing nearly -26%.
Collection
[
|
...
]